Autopsy report · NCT03275597

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“slow accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 5 months before it started.
Ran for about 2 years 4 months before it stopped.
17 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: University of Wisconsin, Madison
Sponsor type: University, hospital or other
Conditions: Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage IV
Interventions: Durvalumab; Tremelimumab; Stereotactic Body Radiotherapy
Participants: 17
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.